FDA delays decision on Stealth’s Barth syndrome drug; TargetRx raises $50Mnews2025-01-23T15:43:35+00:00January 23rd, 2025|Endpoints News|
Shanghai Bao, Sichuan Biokin file IPOs in Hong Kong; Disc’s $200M offeringnews2025-01-22T15:33:23+00:00January 22nd, 2025|Endpoints News|
FDA puts Atara’s INDs on hold after rejection; Ascletis’ safety data for obesity pillnews2025-01-21T15:22:39+00:00January 21st, 2025|Endpoints News|
WuXi AppTec sells medical device testing unit; Layoffs at Notch Therapeuticsnews2025-01-17T15:54:20+00:00January 17th, 2025|Endpoints News|
Boehringer’s schizophrenia asset fails Phase 3; GSK buys organoid biotechnews2025-01-16T15:08:38+00:00January 16th, 2025|Endpoints News|
Hinge Bio’s $30M raise; Keros reports additional issues in Phase 2 PAH trialnews2025-01-15T15:33:05+00:00January 15th, 2025|Endpoints News|
Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loannews2025-01-14T16:18:49+00:00January 14th, 2025|Endpoints News|
Immunovant’s $450M private placement; Biomea becomes an obesity biotechnews2025-01-13T16:17:53+00:00January 13th, 2025|Endpoints News|
Stemson Therapeutics shutters; Insilico teams up again with Menarininews2025-01-10T15:45:09+00:00January 10th, 2025|Endpoints News|
Numab extends its Series C; AnaCardio raises $19M for its heart failure drugnews2025-01-09T15:19:43+00:00January 9th, 2025|Endpoints News|
